Commodity Channel Index
|Bid||60.00 x 800|
|Ask||80.50 x 1200|
|Day's Range||64.91 - 70.80|
|52 Week Range||43.29 - 102.98|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.67|
In this article we will take a look at whether hedge funds think Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC), thyroid cancer and other solid tumors. Registrational data for pralsetinib in patients with RET fusion-positive NSCLC showed deep and durable clinical responses, with a median duration of response (DOR) not reached. Additional results showed the broad clinical activity of pralsetinib across other RET fusion-positive tumors, including thyroid cancer. Pralsetinib was well-tolerated and safety results were consistent with prior data, with no new safety signals observed. These results are being presented during the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program.
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming investor conferences:
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers. The data will also be presented in the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, May 29-31, 2020.
Shares of the company fell 3.5% to $62.02 in premarket trading. The regulator in its so-called complete response letter said that Blueprint's application could not be approved in the current form. The company was looking to win approval for the therapy, Ayvakit, in patients with gastrointestinal stromal tumor (GIST), who have exhausted all other treatment options.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib for the treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor (GIST). The CRL states that the FDA cannot approve the application.
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis.
Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines conference call. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' first-quarter 2020 financial and operating results conference call.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 1.86% and 27.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the first quarter ended March 31, 2020.
A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.
Right now, Blueprint Medicines Inc. (NASDAQ: BPMC) share price is at $59.15, after a 16.6% decrease. Over the past month, the stock spiked by 1.15%, but over the past year, it actually decreased by 20.37%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently trading above from its 52 week low by 36.64%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Blueprint Medicines has a lower P/E than the aggregate P/E of 6.08 of the biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Stocks That Hit 52-Week Lows On Tuesday * Stocks That Hit 52-Week Highs On Tuesday * Sharps Compliance: Q3 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avapritinib versus regorafenib in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST). The VOYAGER trial did not meet the primary endpoint of an improvement in progression-free survival (PFS) for avapritinib versus regorafenib. Top-line safety data for avapritinib were consistent with those previously reported.
If you own shares in Blueprint Medicines Corporation (NASDAQ:BPMC) then it's worth thinking about how it contributes...
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide progress against the company's 2020 goals. These milestones include the compilation of top-line data for pralsetinib in patients with RET-mutant medullary thyroid cancer (MTC), supporting plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated results from the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis (SM) showing significant clinical improvements versus placebo. In Part 1 of the PIONEER trial, patients treated with avapritinib showed a statistically significant mean decline of approximately 30 percent in total symptom score (TSS) at 16 weeks, as measured by the Indolent SM Symptom Assessment Form (ISM-SAF), and reductions in symptom scores have deepened over time. In addition, patients treated with avapritinib achieved consistent improvements across objective measures of mast cell burden and patient-reported quality of life. Avapritinib was well-tolerated with no patients discontinuing treatment due to adverse events (AEs). Based on the full Part 1 data, 25 mg once daily (QD) has been selected as the recommended Part 2 dose (RP2D). Results from this data presentation will be available on an American Academy of Allergy, Asthma & Immunology (AAAAI) virtual forum, which was established following the cancellation of the 2020 AAAAI Annual Meeting: https://education.aaaai.org/annual-meeting-abstracts/.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed previously announced plans to host a live conference call and webcast on Monday, March 16, 2020 to report updated data from Part 1 of the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis, following the cancellation of the 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
[Editor's note: "5 Biotech Stocks to Buy for a Strong Growth Prognosis" was previously published in December 2019. It has since been updated to include the most relevant information available.]Biotech stocks have to be the ultimate risk and reward equities. No other sector comes close to the return potential of the sector. Just take a look at the gains for the SPDR S&P Biotech ETF (NYSE:XBI). The ETF and sector benchmark has managed to post average annual returns of nearly 19% over the last decade. That's pretty insane and underscores the kind of potential that biotech stocks can have.But they also come with a ton of risk to get that return. They don't call them lotto tickets for anything. Many biotech stocks are just one bad trial away from crashing, burning and causing plenty of heartache for their shareholders.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, there are ways to hedge your bets.Aside from going into a broad ETF like the XBI, the key is making sure that investors focus on developmental pipelines, partnership and plenty of cash on their balance sheets. Having a drug actually in the marketing stages doesn't hurt either. It's here that investors can find success in the sector. * 8 Stocks to Buy in March for a Coronavirus Rebound With that in mind, here are five biotech stocks that have plenty of potential. Galapagos NV (GLPG)Source: Shutterstock A good way to spot top clinical-stage and early-entry biotech stocks is finding those firms with top-notch partners. And Galapagos NV (NASDAQ:GLPG) couldn't have picked a better partner than biotech royalty Gilead Sciences (NASDAQ:GILD). Last year, GILD upped its partnership stake in GLPG via a nearly $4 billion payment as well as a $1.1 billion equity stake. All in all, Gilead will now own 22% of Galapagos.There's a good reason why GILD would want to pony up that kind of cash for the biotech firm. It needs to fill potential revenue holes in its aging pipeline and GLPG has the goods.Galapagos has one of the richest and largest development pipelines around. The drug company has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. This includes its potential blockbuster in Filgotinib.This was the first partnership with Gilead and after impressive phase-3 data for the rheumatoid arthritis drug, the duo submitted a marketing application with the FDA earlier this month. Meanwhile, successful initial idiopathic pulmonary fibrosis data, as well as beginning trials for new cystic fibrosis medicines, could all bare significant fruit for GLPG.That's an impressive amount of "shots on goal" for a clinical-stage biotech stock. The best part is, based on the rich deal, the speculation is that Galapagos wanted to stay independent rather than receive a full buyout from GILD. This means it can make the full use of that pipeline with future royalty and milestone payments. It also means investors in GLPG stock can as well. Blueprint Medicines (BPMC)Source: Shutterstock There are a few mega-trends in the world of biotech stocks. Gene therapy is a major one. Another is the concept of small-molecule drugs. Small-molecule drugs are generally more stable than their biologic counterparts and can more commonly be taken as pills as opposed to injections.Though some injected biologics can be taken outside of a healthcare setting (notably Abbvie's (NYSE:ABBV) Humira), many need to be administered by a doctor, nurse or other medical professional. This makes small-molecule drugs better for accessibility and ongoing treatments.This focus on small-molecule drugs makes Blueprint Medicines (NASDAQ:BPMC) a potential real winner among the biotech stocks. * 10 Stocks That Every 20-Year-Old Should Buy BPMC current roster of developmental drugs focuses on various cancers. And the beauty is that pill-delivery system. It really works. Avapritinib -- which treats systemic macrocytosis (SM) and gastrointestinal stromal tumors (GIST) -- managed to shrink these tumors in 86% of the patients treated.That's a high percentage for any study. The late trial success allowed Blueprint to submit a marketing application to the FDA for it. The firm has also seen great success targeting other cancers in several other early trials -- with the small -molecule delivery system leading the way.These successes allowed BPMC to plot its course of action for next year. That should include two marketed drugs, four in application stages and more than a dozen in trials and preclinical investigation. Given the wins already, there's no reason to think blueprint won't get there. Ligand Pharmaceuticals (LGND)Source: Shutterstock If one partner is good, then having more than 100 is better. And this is the case for Ligand Pharmaceuticals (NASDAQ:LGND). LGND counts big shots like Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE) and generic drug specialist Teva (NASDAQ:TEVA) as some of its partners/licensees. The key is Ligand's business model.Ligand doesn't actually develop drugs itself. What it does is provide development platforms that help other biotech stocks and pharmaceutical companies create drugs more effectively. That huge difference has allowed Ligand to quietly become one of the sector's secret stars.Ligand gets upfront payments, development milestones and backend payments on sales after the drugs hit the marketing stages. So far, at least nine drugs using Ligand's tech have been approved. But many more are in the late stages of trials.Perhaps the best part is much of the development risk is pushed on the firms using LGND's tech. Ligand gets paid something either way.As a result, LGND is one of the few biotech stocks out there that is actually profitable. Moreover, the steady stream of royalties has allowed the firm to build up a massive war chest of just under $1.4 billion in cash on its balance sheet. While it's too early to talk about dividend potential, LGND could be on its way to initiating a payout in the future as more drugs hit pharmacy shelves using its technology.And yet, shares of LGND could be a massive bargain. After some hype has left the stock, investors can score shares about 30% below their year-ago levels. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Dominating a disease can mean some big-time revenues for biotech stocks. When it comes to cystic fibrosis, Vertex Pharmaceuticals (NASDAQ:VRTX) is pretty much the only game in town. Three of its FDA-approved drugs -- Kalydeco, Orkambi, and Symdeko -- have a monopoly on the disease.]Its massive foothold on cystic fibrosis treatments have made VRTX a cash cow for investors. Last year, Vertex managed to sell more than $3 billion worth of medicines to treat the disease. However, this year it's looking to eclipse that rate.In 2019, VRTX expects to report product revenue of $3.5 billion to $3.7 billion. That puts it on track to reap more than $5 billion in annual sales by 2024. Those robust sales have also helped balloon its cash balance to nearly $4 billion at the end of the quarter.And the future is robust for Vertex as well. * 7 Ideal Stocks to Buy for Cautious Investors The firm is working on a proven combination therapy of its three drugs to help boost its results further, while Symdeko earlier this year received approval from the FDA to be used in children.The best news for VRTX could be a recent foray into gene editing that could treat cystic fibrosis completely. Partnering with CRISPR Therapeutics (NASDAQ:CRSP), Vertex recently started the first human trial using a CRISPR-based product. That drug -- CTX001 -- also received FDA fast track status and could be a huge revenue booster if approved.With its strong dominance, hefty cash flows and continued sales increases, VRTX has quickly become one of biotech's brightest stars. BioMarin Pharmaceuticals (BRMN)Source: Shutterstock Thanks to continued advances in science and technology, we're able to tackle more rare and orphan diseases. And thanks to their generally small patient population sizes and difficulty of treatment, drugs targeting this niche of the market often come with sky-high prices. For biotech stocks like BioMarin Pharmaceuticals (NASDAQ:BMRN) this is a revenue win.BRMN has made a name for itself by only targeting rare diseases and has the most success in this area. The firm currently has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease.BioMarin has continued to see rising sales and prescriptions for these medications. For example, during the last reported quarter, Vimizim and the PKU franchise managed to generate year-over-year revenue growth of 33% and 23%, respectively. All in all, total revenues for BRMN topped $460 million.And those revenues could keep soaring into the future.For one thing, rare disease medications often come with longer exclusivity rights. This gives BMRN a very long runway to ward off generic competition. Secondly, rare disease medications generally have no trouble getting covered by health insurers. This allows patients to actually get their hands on the high-priced meds in the first place.Adding in BioMarin's beefy pipeline and you have a recipe for success. Analysts expect the firm to finally start turning a profit by 2020 -- especially if its new hemophilia drug turns out to be a blockbuster.Disclosure: At the time of writing, Aaron Levitt was Long CRSP and the iShares NASDAQ Biotechnology ETF (IBB) -- which owns all the stocks on this list. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Large-Cap Dividend Stocks to Buy * 3 of the Worst ETFs in 2019 * 7 Biotech Stocks to Buy and Hold in 2020 The post 5 Biotech Stocks to Buy for a Strong Growth Prognosis appeared first on InvestorPlace.